Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations.
You may also be interested in...
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.
China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
BEIJING - In a step toward lifting a longstanding veil on the drug review process in China, the State FDA has for the first time issued a public outline of the range and types of medicines approved by regulators last year